There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Krystal Biotech Inc (KRYS) and Rocket Pharmaceuticals Inc (RCKT) with bullish sentiments.
Krystal Biotech Inc (KRYS)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Krystal Biotech Inc, with a price target of $59. The company’s shares closed last Monday at $42.27.
Pantginis commented:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $59 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our model currently received the majority of valuation contribution from KB103 for the treatment of DEB patients (89%), with modest contribution from KB105 for ARCI. We believe potential upside exists as clinical data are delivered from both of these assets, as well as potential contribution from pipeline development.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.1% and a 29.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Inc., Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech Inc with a $68.50 average price target, implying a 64.9% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Rocket Pharmaceuticals Inc (RCKT)
William Blair analyst Raju Prasad maintained a Buy rating on Rocket Pharmaceuticals Inc today. The company’s shares closed last Monday at $11.11, close to its 52-week low of $10.75.
Prasad commented:
“Registration-Enabling U.S. Phase II the market opened on Wednesday , Pharma announced plans to initiate a Phase II clinical trial of RP-L102 “Process B” for the treatment of Fanconi anemia (FA) in the fourth quarter , based on recent feedback from the FDA during an end-of-Phase I meeting. The agreed-upon Phase II trial design will include the primary endpoint of resistance to mitomycin-C (MMC) in bone marrow cells at a minimum of one year from treatment to demonstrate reversion of hematopoietic cell sensitivity to DNA-damaging agents. The planned U.S. Phase II trial will enroll up to 5 patients with no upper age limit and who have not developed severe bone marrow failure.”
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.9% and a 49.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics Inc, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on Rocket Pharmaceuticals Inc is a Strong Buy with an average price target of $37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
